Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Sty ...

Merit Medical Systems, Inc. (MMSI) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 37.9% compared with the industry’s growth of 3.6%. The S&P 500 composite has risen 24% in the same period.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Merit Medical specializes in providing products for peripheral and cardiac interventions, targeting conditions in interve ...

Have you been paying attention to shares of Merit Medical (MMSI) ? Shares have been on the move with the stock up 8.8% over the past month. The stock hit a new 52-week high of $102.88 in the previous session. Merit Medical has gained 34.2% since the start of the year compared to the 4% move for the Zacks Medical sector and the 4.3% return for the Zacks Medical - Dental Supplies industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ear ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical’s lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. “We are pleased to ...

Merit Medical Systems, Inc. (MMSI) reported third-quarter 2024 adjusted earnings per share (EPS) of 86 cents, up 21.1% from the year-ago quarter. The bottom line surpassed the Zacks Consensus Estimate by 7.5%.GAAP EPS for the quarter was 48 cents, up 9.1% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.MMSI’s Revenue DetailsRevenues grossed $339.8 million in the reported quarter, up 7.8% year over year. The metric topped the Zacks Consensus Estimate by 1.4%.Total revenu ...

财务数据和关键指标变化 - 公司第三季度总收入为3.398亿美元，同比增长7.8%，按固定汇率计算同比增长7.9% [11] - 非GAAP营业利润增长19%，非GAAP营业利润率为19.2%，同比上升约175个基点 [13] - 非GAAP每股收益增长21%，超出预期 [13] - 第三季度自由现金流为3800万美元，2024年前九个月自由现金流超过1.2亿美元，同比增长116% [14][55] 各条业务线数据和关键指标变化 - 心血管业务增长6%，内窥镜业务增长86% [37] - 外周介入产品销售增长7.7%，占心血管业务增长的近60% [38] - 自定义程序解决方案产品销售增长4% [39] - 心脏介入产品销售增长2% [40] 各个市场数据和关键指标变化 - 美国市场销售增长10%，按固定汇率计算增长7% [43] - 国际市场销售增长4.5%，按固定汇率计算增长4.4% [45] - 中国市场销售下降5.1%，但好于预期 [46] 公司战略和发展方向和行业竞争 - 公司计划收购Cook Medical的引导管理产品组合，交易金额约为2.1亿美元，预计将增强心脏介入市场的竞争力 [16][21] - 公司专注于持续的强劲执行、盈利能力提升和自由现金流增长 [15] - 公司预计2025财年将实现超过1亿美元的年化电生理和心脏节律管理收入 [23] 管理层对经营环境和未来前景的评论 - 管理层对未来的经营环境持乐观态度，认为公司在各个业务线和市场上都表现出强劲的增长势头 [14][56] - 管理层提到，尽管面临供应链挑战，需求依然强劲，预计OEM销售增长约7% [42][116] 其他重要信息 - 公司更新了2024财年的财务指引，预计总收入增长6.9%至7.6% [58] - 公司预计2024年自由现金流约为1.5亿美元，较之前的1.3亿美元有所上调 [56] 问答环节所有提问和回答 问题: 关于Cook收购的协同效应 - 管理层表示，收购将有助于建立以电生理为重点的销售团队，推动现有产品的销售 [70][71] 问题: WRAPSODY的定价策略 - 管理层确认将根据NTAP的预期进行定价，但具体情况将在FDA批准后进一步明确 [72] 问题: WRAPSODY在欧洲的市场反应 - 管理层认为，尽管数据发布后反响良好，但市场接受度需要时间 [75][76] 问题: OEM业务的未来增长 - 管理层对OEM业务的需求持乐观态度，认为物流问题是孤立事件，不会影响长期增长 [112][116] 问题: WRAPSODY的市场机会 - 管理层表示，WRAPSODY的市场机会将在FDA批准后进行详细讨论 [99][100]

Merit Medical (MMSI) reported $339.85 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 7.8%. EPS of $0.86 for the same period compares to $0.75 a year ago. View all Key Company Metrics for Merit Medical here>>> The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $335.02 million. With the consensus EPS estimate being $0.80, the EPS surprise was +7.50%. While investors closely watch year-over-year changes in headline numbe ...

业绩总结 - 2024年第三季度收入为3.398亿美元，较2023年第三季度的3.152亿美元增长7.8%[4] - 2024年第三季度净收入为2840万美元，较2023年第三季度的2580万美元增长10.1%[4] - 2024年第三季度每股收益为0.48美元，较2023年第三季度的0.44美元增长8.0%[4] - 2024年截至第三季度的年初至今收入为10.014亿美元，较2023年同期的9.329亿美元增长7.3%[4] - 2024年第三季度非GAAP收入为3.333亿美元，较2023年第三季度的3.152亿美元增长5.7%[5] - 2024年第三季度非GAAP净收入为5120万美元，较2023年第三季度的4140万美元增长23.5%[5] 市场表现 - 2024年美国市场收入为5.8725亿美元，较2023年同期的5.38447亿美元增长9.1%[7] - 2024年国际市场总收入为4.14106亿美元，较2023年同期的3.94404亿美元增长5.0%[7] 未来展望 - 2024年更新的净销售指导为13.44亿至13.52亿美元，同比增长6.9%至7.6%[9] - 2024年更新的每股收益指导为3.33至3.38美元，同比增长17%至19%[9] Merit财务数据 - 2024年第三季度，Merit的GAAP净收入为28,444千美元，非GAAP净收入为51,151千美元，非GAAP每股收益为0.86美元[22] - 2024年前九个月，Merit的GAAP净收入为92,410千美元，非GAAP净收入为149,034千美元，非GAAP每股收益为2.53美元[23] - 2024年第三季度，Merit的非GAAP毛利为66,009千美元，非GAAP毛利率为86%[22] - 2024年前九个月，Merit的非GAAP毛利为189,961千美元，非GAAP毛利率为79%[23] 成本与费用 - 2024年第三季度的摊销费用为14,896千美元，占销售额的4.4%，2023年同期为13,120千美元，占4.2%[24] - 2024年第三季度的医疗器械法规合规费用为1,983千美元，占销售额的0.6%，2023年同期为2,444千美元，占0.8%[24] - 2024年第三季度的企业重组费用为2,084千美元，占销售额的0.6%[24] 其他财务指标 - 2024年第三季度的非GAAP毛利率为50.9%，2023年同期为49.8%[31] - 2024年第三季度的有机恒定货币收入为333,321千美元，同比增长5.7%[30] - 2024年第三季度的外汇影响为281千美元，2023年同期为5,006千美元[30]

Merit Medical (MMSI) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 7.50%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.88 per share when it actually produced earnings of $0.92, delivering a surprise of 4.55%. Over the last f ...